Endoret® PRGF®
Endoret® (PRGF®) is a platelet-rich plasma (PRP) technology for obtaining autologous proteins from the patient’s own blood.
BTI Biotechnology Institute
BTI is considered a worldwide scientific reference in regenerative medicine. This recognition is the result of the successful use of Endoret® (PRGF®) in different medical specialties such as dentistry, traumatology, dermatology, ophthalmology, sports medicine, vascular surgery, aesthetics, among others.
Endoret® PRGF® is a closed system, with the necessary equipment and unitary and disposable kits certified for such use that allows a rapid preparation of plasma under sterile conditions and its immediate application.
Advantages of PRGF®:
> Autologous and rich in Growth Factors
- Taken from patient’s blood, so there is less possibility of side effects
- It promotes homeostasis
- Stimulates cell proliferation and migration
- It stimulates the endogenous secretion of proteins from the extracellular matrix
> Optimal concentration of Growth Factors
- Platelet concentration compared to baseline between 2 and 3 times
- Balance between growth factors:
- Platelet-based (released by platelets)
- Plasma-based (present free in plasma)
> Free from leukocytes and inflammatory proteins
- Process includes elimination of leukocytes, Complement C and IgE
- Preserves the integrity of the fibrin matrix over time
> Controlled activation
- Promotes the release of growth factors from platelet
- Induces polymerisation of the fibrin matrix
> Scientific evidence
- Technology endorsed by more than 200 indexed scientific publications
BTI Biotechnology Institute
BTI is considered a worldwide scientific reference in regenerative medicine. This recognition is the result of the successful use of Endoret® (PRGF®) in different medical specialties such as dentistry, traumatology, dermatology, ophthalmology, sports medicine, vascular surgery, aesthetics, among others.
Endoret® PRGF® is a closed system, with the necessary equipment and unitary and disposable kits certified for such use that allows a rapid preparation of plasma under sterile conditions and its immediate application.
Advantages of PRGF®:
> Autologous and rich in Growth Factors
- Taken from patient’s blood, so there is less possibility of side effects
- It promotes homeostasis
- Stimulates cell proliferation and migration
- It stimulates the endogenous secretion of proteins from the extracellular matrix
> Optimal concentration of Growth Factors
- Platelet concentration compared to baseline between 2 and 3 times
- Balance between growth factors:
- Platelet-based (released by platelets)
- Plasma-based (present free in plasma)
> Free from leukocytes and inflammatory proteins
- Process includes elimination of leukocytes, Complement C and IgE
- Preserves the integrity of the fibrin matrix over time
> Controlled activation
- Promotes the release of growth factors from platelet
- Induces polymerisation of the fibrin matrix
> Scientific evidence
- Technology endorsed by more than 200 indexed scientific publications
Endoret® (PRGF®): closed technique
What is the difference between the closed and the open technique?
- Closed technique:
- Utilizes disposable, single-use kits; the instructions given by the manufacturer of each system must be followed without it being necessary to obtain a certificate of adequacy from the facilities.
- Open technique:
- The method for obtaining PRP should be evaluated and authorised by an inspection by the competent health regulation to verify the suitability of the facilities and the production activities.
Interested to know more about Endoret® (PRGF®)?
Click Here to access resources and contact us directly.
Resources include – “How do I prescribe Endoret® (PRGF®) to my patients?’ and a patient video to download.
References – Click Here for the Literature Review
Anitua E, de la Sen-Corcuera B, Orive G, Sánchez-Ávila RM, Heredia P, Muruzabal F, Merayo-Lloves J. Progress in the use of plasma rich in growth factors in ophthalmology: from ocular surface to ocular fundus. Expert Opin Biol Ther. 2021 Jul 19:1-15. doi: 10.1080/14712598.2021.1945030.
Anitua E, de la Fuente M, Muruzabal F, Riestra A, Merayo-Lloves J, Orive G. Plasma rich in growth factors (PRGF) eye drops stimulates scarless regeneration compared to autologous serum in the ocular surface stromal fibroblasts. Exp Eye Res. 2015 Jun;135:118-26. doi: 10.1016/j.exer.2015.02.016.
Freire V, Andollo N, Etxebarria J, Hernáez-Moya R, Durán JA, Morales MC. Corneal wound healing promoted by 3 blood derivatives: an in vitro and in vivo comparative study. Cornea. 2014 Jun;33(6):614-20. doi: 10.1097/ICO.0000000000000109.
Merayo-Lloves J, Sanchez-Avila RM, Riestra AC, et al. Safety and Efficacy of Autologous Plasma Rich in Growth Factors Eye Drops for the Treatment of Evaporative Dry Eye. Ophthalmic Res. 2016;56(2):68-73. doi:10.1159/000444496
Sanchez-Avila RM, Merayo-Lloves J, Riestra AC, et al. Treatment of patients with neurotrophic keratitis stages 2 and 3 with plasma rich in growth factors (PRGF-Endoret) eye-drops. Int Ophthalmol. 2018;38(3):1193-1204. doi:10.1007/s10792-017-0582-7